NEW YORK (GenomeWeb) – OncoCyte said after the close of the market on Tuesday that its third quarter net loss narrowed year over year as it continues to advance the development of its flagship liquid biopsy test toward commercialization.

For the three months ended Sept. 30, the Alameda, California-based diagnostic developer incurred a net loss of $3.0 million, or $.07 per share, compared to a loss of $6.9 million, or $.22 per share, in the year-ago period.

OncoCyte did not report any Q3 revenues.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.